Showing results (311-320 of 408) with videos related to

Sort By:
Pageof 41
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 14, 2019
Multidrug-resistant Organisms in Hospitals: What Is on Patient Hands and in Their Rooms?Lona Mody, Laraine L Washer, Keith S Kaye, et al.
Infection Control and Hospital Epidemiology|April 5, 2011
The network approach for prevention of healthcare-associated infections: long-term effect of participation in the Duke Infection Control Outreach NetworkDeverick J Anderson, Becky A Miller, Luke F Chen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 14, 2024
Lowering the Acquisition of Multidrug-Resistant Organisms (MDROs) With Pulsed-xenon (LAMP) Study: A Cluster-Randomized, Controlled, Double-Blinded, Interventional Crossover TrialSorabh Dhar, Chetan Jinadatha, Paul E Kilgore, et al.
Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society|May 17, 2021
Efficacy of clotrimazole for the management of oral candidiasis: A meta-analysis of randomized clinical trialsThamer A Almangour, Keith S Kaye, Mohammed Alessa, et al.
Circulation|June 25, 2003
Staphylococcus aureus bacteremia after median sternotomy: clinical utility of blood culture results in the identification of postoperative mediastinitisVance G Fowler, Keith S Kaye, David L Simel, et al.
Frontiers in Pharmacology|October 22, 2019
Synergistic Combination of Polymyxin B and Enrofloxacin Induced Metabolic Perturbations in Extensive Drug-Resistant Pseudomonas aeruginosaYu-Wei Lin, Mei-Ling Han, Jinxin Zhao, et al.
The Lancet. Infectious Diseases|December 3, 2014
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensusRoger L Nation, Jian Li, Otto Cars, et al.
The Lancet. Infectious Diseases|October 15, 2020
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trialRichard G Wunderink, Yuko Matsunaga, Mari Ariyasu, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2017
Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activityJustin R Lenhard, Visanu Thamlikitkul, Fernanda P Silveira, et al.
The Lancet. Infectious Diseases|May 14, 2023
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)Keith S Kaye, Andrew F Shorr, Richard G Wunderink, et al.
Pageof 41